149324-24-3

Usage

Uses

Used in Pharmaceutical Industry:
2-isopropyl-1,3,4-oxadiazole is used as a chemical precursor for the synthesis of various pharmaceuticals. Its unique structure allows for the creation of new compounds with potential therapeutic applications, making it a valuable component in drug development.
Used in Agrochemical Industry:
In the agrochemical sector, 2-isopropyl-1,3,4-oxadiazole is employed as a starting material for the production of agrochemicals. Its incorporation into these products can contribute to the development of more effective and targeted pest control solutions.
Used in Fragrance and Flavoring Industry:
2-isopropyl-1,3,4-oxadiazole is utilized as a building block in the creation of fragrances and flavorings. Its chemical properties enable the production of a wide range of scents and tastes, enhancing the sensory experience of various consumer products.
Used in Research and Development:
2-isopropyl-1,3,4-oxadiazole is used as a subject of study in research and development settings. Its potential pharmacological properties, such as antimicrobial and antitumor activities, are being investigated to explore its possible applications in the medical field, including the development of new treatments for various diseases.

InChI:InChI=1/C5H8N2O/c1-4(2)5-7-6-3-8-5/h3-4H,1-2H3

Upstream product

• 3619-17-8 isobutyric acid hydrazide 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 1026312-25-3 [2-(4-Fluoro-phenyl)-1-({(S)-1-[hydroxy-(5-isopropyl-[1,3,4]oxadiazol-2-yl)-methyl]-2-methyl-propylcarbamoyl}-methyl)-6-oxo-1,6-dihydro-pyrimidin-5-yl]-carbamic acid benzyl ester 
• 1026531-06-5 (2-(4-Fluoro-phenyl)-1-{[(S)-1-(5-isopropyl-[1,3,4]oxadiazole-2-carbonyl)-2-methyl-propylcarbamoyl]-methyl}-6-oxo-1,6-dihydro-pyrimidin-5-yl)-carbamic acid benzyl ester 

Relevant academic research and scientific papers

COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME

The present specification provides a compound represented by chemical formula 1 and an organic light emitting device including the same. The compound may improve lifespan characteristics of the organic light emitting device.

Keto-1,3,4-oxadiazoles as cathepsin K inhibitors

We have prepared a series of cathepsin K inhibitors bearing the keto-1,3,4-oxadiazole warhead capable of forming a hemithioketal complex with the target enzyme. By modifying binding moieties at the P1, P2, and prime side positions of the inhibitors, we have achieved selectivity over cathepsins B, L, and S, and have achieved sub-nanomolar potency against cathepsin K. This series thus represents a promising chemotype that could be used in diseases implicated by imbalances in cathepsin K activity such as osteoporosis.

Development of orally active nonpeptidic inhibitors of human neutrophil elastase

5-Amino-2-phenylpyrimidin-6-ones, some of their desamino derivatives, and miscellaneous derivatives were synthesized and biologically evaluated on both in vitro activity and oral activity in an acute hemorrhagic assay. These compounds contained an α-keto-1,3,4-oxadiazole moiety to bind covalently to the Ser-195 hydroxy group of human neutrophil elastase (HNE). Among those tested, compounds 11a-c,e,i-l(F), 11d,e,k(H), 21d,e,k(F), and 21d,e(H) showed a good oral profile. RS-Mixture 3(H) was selected for clinical evaluation based on its oral potency, duration of action, enzyme selectivity, safety profile, and ease of synthesis. Structure -activity relationships (SARs) are discussed.